Enlivex Therapeutics Ltd (ENLV)

$1.44

+0.07

(+5.11%)

Market is closed - opens 7 PM, 24 Jul 2024

Performance

  • $1.37
    $1.46
    $1.44
    downward going graph

    5.2%

    Downside

    Day's Volatility :6.5%

    Upside

    1.37%

    downward going graph
  • $1.15
    $4.59
    $1.44
    downward going graph

    20.14%

    Downside

    52 Weeks Volatility :74.95%

    Upside

    68.63%

    downward going graph

Returns

PeriodEnlivex Therapeutics LtdIndex (Russel 2000)
3 Months
3.79%
0.0%
6 Months
-50.9%
0.0%
1 Year
-46.69%
0.0%
3 Years
-81.59%
-19.9%

Highlights

Market Capitalization
28.3M
Book Value
$1.43
Earnings Per Share (EPS)
-1.39
Wall Street Target Price
6.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-30.63%
Return On Equity TTM
-67.14%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-21.5M
Diluted Eps TTM
-1.39
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.81
EPS Estimate Next Year
-0.59
EPS Estimate Current Quarter
-0.25
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Enlivex Therapeutics Ltd(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 316.67%

Current $1.44
Target $6.00

Technicals Summary

Sell

Neutral

Buy

Enlivex Therapeutics Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd
-2.84%
-50.9%
-46.69%
-81.59%
-94.17%
Moderna, Inc.
Moderna, Inc.
-10.58%
20.19%
-0.41%
-64.88%
800.74%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.55%
12.06%
47.12%
82.44%
245.9%
Novo Nordisk A/s
Novo Nordisk A/s
-6.4%
26.39%
64.35%
193.51%
440.83%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.41%
12.78%
38.89%
147.34%
182.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd
NA
NA
NA
-0.81
-0.67
-0.31
NA
1.43
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.45
31.45
1.46
44.4
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.05
45.05
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd
Buy
$28.3M
-94.17%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.4B
800.74%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.2B
245.9%
31.45
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.7B
440.83%
45.05
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
182.99%
31.94
39.46%

Insights on Enlivex Therapeutics Ltd

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 60.8% return, outperforming this stock by 105.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.5% return, outperforming this stock by 275.1%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    0.35%
  • Renaissance Technologies Corp

    0.33%
  • Susquehanna International Group, LLP

    0.33%
  • SIMPLEX TRADING, LLC

    0.09%
  • Geode Capital Management, LLC

    0.05%
  • Wells Fargo & Co

    0.05%

Company Information

enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib clinical trial in patients with severe sepsis; that is in investigator-initiated phase ii clinical trial for the treatment of covid-19 patients in severe and critical conditions; and which is in phase iia clinical trial for the prevention of graft versus host disease in allogeneic hematopoietic stem cell transplants (hsct) patients. the company is also developing allocetra for the prevention of complications associated with bone marrow transplantations and/or hsct, and acute multiple organ failure. it also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor t-cell therapy and therapies targeting t-cell re

Organization
Enlivex Therapeutics Ltd
Employees
0
CEO
Mr. Shai Novik M.B.A.
Industry
Biotechnology

FAQs